Table 4 Mortality rates of patients with eGFR < 30 or dialysis who received levosimendan versus dobutamine alone
Outcomes | Event (%) | Levosimendan vs. dobutamine | ||
|---|---|---|---|---|
Levosimendan | Dobutamine | HR (95% CI) | P value | |
Before PSM patient numbers | 52 | 374 | ||
In-hospital mortality | 14 (26.9) | 114 (30.5) | 0.76 (0.44–1.32) | 0.330 |
5-day mortality | 5 (9.6) | 45 (12.0) | 0.79 (0.31–1.98) | 0.611 |
14-day mortality | 11 (21.2) | 76 (20.3) | 1.01 (0.54–1.91) | 0.968 |
30-day mortality | 11 (21.2) | 104 (27.8) | 0.73 (0.39–1.37) | 0.330 |
90-day mortality | 14 (26.9) | 132 (35.3) | 0.72 (0.42–1.25) | 0.247 |
180-day mortality | 18 (34.6) | 148 (39.6) | 0.83 (0.51–1.36) | 0.457 |
After PSM patient numbers | 43 | 81 | ||
In-hospital mortality | 13 (30.2) | 30 (37.0) | 0.67 (0.36–1.26) | 0.212 |
5-day mortality | 4 (9.3) | 10 (12.3) | 0.76 (0.26–2.22) | 0.611 |
14-day mortality | 10 (23.3) | 21 (25.9) | 0.87 (0.42–1.80) | 0.707 |
30-day mortality | 10 (23.3) | 28 (34.6) | 0.65 (0.30–1.37) | 0.254 |
90-day mortality | 13 (30.2) | 34 (42.0) | 0.68 (0.35–1.31) | 0.248 |
180-day mortality | 17 (39.5) | 36 (44.4) | 0.84 (0.45–1.55) | 0.573 |